Vascularized retinal pigment epithelial detachment in age-related macular degeneration: treatment and RPE tear incidence

  • Ugo IntroiniEmail author
  • Ana Torres Gimeno
  • Fabrizio Scotti
  • Marco Setaccioli
  • Silvia Giatsidis
  • Francesco Bandello
Retinal Disorders



To review vascularized-pigment epithelial detachment (V-PED) treatment visual outcome, and to assess acute retinal pigment epithelium (RPE) tear incidence.


One hundred and thirty-two eyes of 125 consecutive patients with age-related macular degeneration and V-PED were included. Ninety-four eyes (71.2%) were associated with choroidal new vessels (CNV), 38 (28.8%) with retinal angiomatous proliferation (RAP). Patients, treated over a 10-year period with the time-current therapy, received: verteporfin photodynamic therapy (PDT) (group 1, 38 eyes), combined intravitreal triamcinolone acetonide (IVTA) and PDT (group 2, 44 eyes) or intravitreal anti-VEGF injection (bevacizumab or ranibizumab) (group 3, 50 eyes).


Mean follow-up was 20.5 months. At month 12, all eyes treated with PDT or with IVTA and PDT showed a mean significant severe visual decrease. Eyes with CNV lost −0.67 and −0.37 logMAR (p < 0.01 and p < 0.01 respectively), and eyes with RAP −0.55 and −0.31 logMAR (p < 0.01 and p = 0.01 respectively). RPE tear occurred in 14 eyes (36.8%) and in six eyes (13.6%) in groups 1 and 2 respectively. Eyes treated with anti-VEGF therapy showed slight mean visual acuity decrease at month 12. Those with CNV had a mean baseline best-corrected visual acuity (BCVA) of 0.36 ± 0.24 logMAR, final of 0.44 ± 0.30 logMAR (−0.08 logMAR, n.s.). In eyes with RAP, mean baseline BCVA was 0.58 ± 0.39 logMAR, final was 0.78 ± 0.47 logMAR (−0.20 logMAR, n.s.). RPE tear occurred in 14 eyes (36.8%). Patients with either V-PED with CNV or a better baseline BCVA showed greater risk of acute RPE tear (p = 0.01 and p = 0.003 respectively).


Effective treatment for vascularized PED is still lacking. Until now, only stabilization of the disease has been achieved using anti-VEGF therapy, but the risk of RPE tear can further hamper our expectations. Baseline characteristics are helpful for prognosis, but patients must be informed of the uncertain response. New therapeutic strategies are needed.


Age-related macular degeneration Retinal pigment epithelial detachment Choroidal neovascularization Retinal angiomatous proliferation RPE tear antiVEGF 



The Authors wish to thank Michael John of the Vita-Salute San Raffaele University for the English language editing of this manuscript.

Conflict of interest

Ugo Introini: none. Ana Torres Gimeno: none. Fabrizio Scotti: none. Marco Setaccioli: none. Silvia Giatsidis: none. Francesco Bandello: Novartis Pharmaceuticals Corporation; Allergan, Inc.; Alcon, Inc.; Bayer Schering Pharma; Farmila-THEA; Genentech, Inc.; Pfizer, Inc.; Bausch & Lomb.

Financial support



  1. 1.
    Yannuzzi LA, Hope-Ross M, Slakter JS, Guyer DR, Sorenson JA, Ho AC, Sperber DE, Freund KB, Orlock DA (1994) Analysis of vascularized pigment epithelial detachments using indocyanine green videoangiography. Retina 14:99–113PubMedCrossRefGoogle Scholar
  2. 2.
    Zayit-Soudry S, Moroz I, Loewenstein A (2007) Retinal pigment epithelial detachment. Surv Ophthalmol 52:227–243PubMedCrossRefGoogle Scholar
  3. 3.
    Cohen SY, Creuzot-Garcher C, Darmon J, Desmettre T, Korobelnik JF, Levrat F, Quentel G, Paliès S, Sanchez A, De Gendre AS, Schluep H, Weber M, Delcourt C (2007) Types of choroidal neovascularization in newly diagnosed exudative age-related macular degeneration. Br J Ophthalmol 91:1173–1176PubMedCrossRefGoogle Scholar
  4. 4.
    Coscas G, Koenig F, Soubrane G (1990) The pretear characteristics of pigment epithelial detachments. A study of 40 eyes. Arch Ophthalmol 108:1687–1693PubMedCrossRefGoogle Scholar
  5. 5.
    Wasmuth S (2010) Pathogenetic concepts for pigment epithelial detachment in exudative AMD. Ophthalmologe 107:1109–1114PubMedCrossRefGoogle Scholar
  6. 6.
    Axer-Siegel R, Ehrlich R, Rosenblatt I, Kramer M, Priel E, Yassur Y, Weinberger D (2004) Photodynamic therapy for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration. Arch Ophthalmol 122:453–459PubMedCrossRefGoogle Scholar
  7. 7.
    Axer-Siegel R, Ehrlich R, Avisar I, Kramer M, Rosenblatt I, Priel E, Weinberger D (2006) Combined photodynamic therapy and intravitreal triamcinolone acetonide injection for neovascular age-related macular degeneration with pigment epithelium detachment. Ophthalmic Surg Lasers Imaging 37:455–461PubMedGoogle Scholar
  8. 8.
    Ritter M, Bolz M, Sacu S, Deak G, Kiss C, Pruente C, Schmidt-Erfurth UM (2010) Effect of intravitreal ranibizumab in avascular pigment epithelial detachment. Eye 24:962–968PubMedCrossRefGoogle Scholar
  9. 9.
    Brancato R, Introini U, Bolognesi G, Pacelli G, Trabucchi G, Pece A (2000) ICGA-guided laser photocoagulation of occult choroidal neovascularization in age-related macular degeneration. Indocyanine green angiography. Retina 20:134–142PubMedCrossRefGoogle Scholar
  10. 10.
    Pece A, Isola V, Vadalà M, Calori G (2007) Photodynamic therapy with verteporfin for choroidal neovascularization associated with retinal pigment epithelial detachment in age-related macular degeneration. Retina 27:342–348PubMedCrossRefGoogle Scholar
  11. 11.
    Arias L (2010) Treatment of retinal pigment epithelial detachment with antiangiogenic therapy. Clin Ophthalmol 4:369–374PubMedCrossRefGoogle Scholar
  12. 12.
    Wygnanski-Jaffe T, Desatnik H, Alhalel A, Goldstein M, Lowenstein A, Zolf R, Moisseiev J (2006) Angiography-guided photodynamic therapy for large pigment epithelial detachments in age-related macular degeneration. Ophthalmic Surg Lasers Imaging 37:358–363PubMedGoogle Scholar
  13. 13.
    Ergun E, Maar N, Ansari-Shahrezaei S, Wimpissinger B, Krepler K, Wedrich A, Stur M (2006) Photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration. Am J Ophthalmol 142:10–16PubMedCrossRefGoogle Scholar
  14. 14.
    Boscia F, Furino C, Sborgia L, Reibaldi M, Sborgia C (2004) Photodynamic therapy for retinal angiomatous proliferations and pigment epithelium detachment. Am J Ophthalmol 138:1077–1079PubMedCrossRefGoogle Scholar
  15. 15.
    Boscia F, Parodi MB, Furino C, Reibaldi M, Sborgia C (2006) Photodynamic therapy with verteporfin for retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol 244:1224–1232PubMedCrossRefGoogle Scholar
  16. 16.
    Saito M, Lida T, Nagayama D (2008) Photodynamic therapy with verteporfin for age-related macular degeneration or polypoidal choroidal vasculopathy: comparison of the presence of serous retinal pigment epithelial detachment. Br J Ophthalmol 92:1642–1647PubMedCrossRefGoogle Scholar
  17. 17.
    Pece A, Introini U, Bottoni F, Brancato R (2001) Acute retinal pigment epithelial tear after photodynamic therapy. Retina 21:661–665PubMedCrossRefGoogle Scholar
  18. 18.
    Gelisken F, Inhoffen W, Partsch M, Schneider U, Kreissig I (2001) Retinal pigment epithelial tear after photodynamic therapy for choroidal neovascularization. Am J Ophthalmol 131:518–520PubMedCrossRefGoogle Scholar
  19. 19.
    Goldstein M, Heilweil G, Barak A, Loewenstein A (2005) Retinal pigment epithelial tear following photodynamic therapy for choroidal neovascularization secondary to AMD. Eye 19:1315–1324PubMedCrossRefGoogle Scholar
  20. 20.
    Lommatzsch A, Heimes B, Gutfleisch M, Spital G, Zeimer M, Pauleikhoff D (2009) Serous pigment epithelial detachment in age-related macular degeneration: comparison of different treatments. Eye 23:2163–2168PubMedCrossRefGoogle Scholar
  21. 21.
    Lai TY, Chan WM, Liu DT, Lam DS (2007) Ranibizumab for retinal angiomatous proliferation in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 245:1877–1880PubMedCrossRefGoogle Scholar
  22. 22.
    Meyerle CB, Freund KB, Iturralde D, Spaide RF, Sorenson JA, Slakter JS, Klancnik JM Jr, Fisher YL, Cooney MJ, Yannuzzi LA (2007) Intravitreal bevacizumab (Avastin) for retinal angiomatous proliferation. Retina 27:451–457PubMedCrossRefGoogle Scholar
  23. 23.
    Kook D, Wolf A, Neubauer AS, Haritoglou C, Priglinger SG, Kampik A, Ulbig MW (2008) Retinal pigment epithelial tears after intravitreal injection of bevacizumab for AMD. Frequency and progress. Ophthalmologe 105:158–164PubMedCrossRefGoogle Scholar
  24. 24.
    Chiang A, Louis K, Chang LK, Yu F (2008) Predictors of anti-VEGF-associated retinal pigment epithelial tear using FA and OCT analysis. Retina 28:1265–1269PubMedCrossRefGoogle Scholar
  25. 25.
    Chen E, Kaiser RS, Vander JF (2007) Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration. Retina 27:445–450PubMedCrossRefGoogle Scholar
  26. 26.
    Golbaz I, Ahlers C, Stock G, Schütze C, Schriefl S, Schlanitz F, Simader C, Prünte C, Schimdt-Erfurth U (2011) Quantification of the therapeutic response of intraretinal, subretinal and subpigmentepithelial compartments in exudative AMD during anti-VEGF therapy. Invest Ophthalmol Vis Sci 52:1599–1605PubMedCrossRefGoogle Scholar
  27. 27.
    Arora S, McKibbin M (2011) One-year outcome after intravitreal ranibizumab for large, serous pigment epithelial detachment secondary to age-related macular degeneration. Eye 25:1034–1038PubMedCrossRefGoogle Scholar
  28. 28.
    Ruppenstein M, Ach T, Hoh A, Dithmar S (2010) Effect of intravitreal bevacizumab on pigment epithelial detachment in occult choroidal neovascularization. Ophthalmologe 107:827–830PubMedCrossRefGoogle Scholar
  29. 29.
    Nicolò M, Ghiglione D, Calabria G (2006) Retinal pigment epithelial tear following intravitreal injection of bevacizumab (Avastin). Eur J Ophthalnol 16:770–773Google Scholar
  30. 30.
    Chang LK, Sarraf D (2007) Tears of the retinal pigment epithelium. An old problem in a new era. Retina 27:523–534PubMedCrossRefGoogle Scholar
  31. 31.
    Smith BT, Kraus CL, Apte RS (2009) Retina pigment epithelial tears in ranibizumab-treated eyes. Retina 29:335–339PubMedCrossRefGoogle Scholar
  32. 32.
    Spandau VHM, Jonas JB (2006) Retinal pigment epithelial tear after intravitreal bevacizumab for exudative age-related macular degeneration. Am J Ophthalmol 142:1068–1070PubMedCrossRefGoogle Scholar
  33. 33.
    Gass JD (1984) Retinal pigment epithelial rip during krypton red laser photocoagulation. Am J Ophthalmol 98:700–706PubMedGoogle Scholar
  34. 34.
    Michels S, Aue A, Simader C, Geitzenauer W, Sacu S, Schmidt-Erfuth U (2006) Retinal pigment epithelium tears following verteporfin therapy combined with intravitreal triamcinolone. Am J Ophthalmol 141:396–398PubMedCrossRefGoogle Scholar
  35. 35.
    Dhalla MS, Blinder KJ, Tewari A, Hariprasad SM, Apte RS (2006) Retinal pigment epithelial tear following intravitreal pegaptanib sodium. Am J Ophthalmol 141:752–754PubMedCrossRefGoogle Scholar
  36. 36.
    Meyer CH, Toth CA (2001) Retinal pigment epithelial tear with vitreomacular traction: a novel pathogenic feature. Graefes Arch Clin Exp Ophthalmol 239:325–333PubMedCrossRefGoogle Scholar
  37. 37.
    Leitritz M, Gelisken F, Inhoffen W, Voelker M, Ziemssen F (2008) Can the risk of retinal pigment epithelium tears after bevacizumab treatment be predicted? An optical coherence tomography study. Eye 22:1504–1507PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Ugo Introini
    • 1
    Email author
  • Ana Torres Gimeno
    • 1
  • Fabrizio Scotti
    • 1
  • Marco Setaccioli
    • 1
  • Silvia Giatsidis
    • 2
  • Francesco Bandello
    • 2
  1. 1.Department of OphthalmologySan Raffaele Scientific InstituteMilanItaly
  2. 2.Department of OphthalmologyUniversity Vita-Salute, San Raffaele Scientific InstituteMilanItaly

Personalised recommendations